KMT2A is a prerequisite of malignant transformation during IDH-mutant gliomagenesis [0.03%]
IDH突变型胶质瘤发生过程中KMT2A是恶性转化的必要条件
Marilin S Koch,Minh Deo,Claudia Schmidt et al.
Marilin S Koch et al.
Background: IDH1R132H is the defining mutation of low-grade gliomas (LGGs), inflicting broad epigenetic rewiring that leads to malignant transformation. Recent studies demonstrated that cell fate change from astrocyte to ...
ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in recurrent glioma: a single-arm, phase 1/2 study [0.03%]
重组溶瘤单纯疱疹病毒1型ON-01治疗复发性胶质瘤的Ⅰ/Ⅱ期单臂研究
Wei Zeng,Peiwen Wang,Sheng Fang et al.
Wei Zeng et al.
Background: The prognosis of patients with recurrent WHO grade 4 glioma is poor, particularly in glioblastoma (GBM), which has a median survival of approximately 6 months and no effective treatment options. We evaluated t...
Tumor Microenvironment Shapes the Spatial Organization of Glioblastoma Cell States [0.03%]
肿瘤微环境塑造胶质母细胞瘤细胞状态的空间组织
Pranav Prakash,James Trippett,Cameron Ehsan et al.
Pranav Prakash et al.
Glioblastoma is characterized by heterogeneous and plastic cellular populations that adopt transcriptional programs shaped by genetic alterations and microenvironmental cues. Recent studies have identified at least four partially inconverti...
SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use Alternative Lengthening of Telomeres [0.03%]
SMARCAL1是ATRX缺陷型端粒替代延长胶质瘤的可药物化合成致死性靶点
Alexandrea Brown,Laura M Strickland,Elise N Erman et al.
Alexandrea Brown et al.
Background: Approximately 10% of cancers achieve replicative immortality through a telomerase-independent mechanism of telomere maintenance, termed Alternative Lengthening of Telomeres (ALT). ALT is particularly prevalent...
Trastuzumab deruxtecan efficacy, FcRn-facilitated penetration of the blood-tumor barrier and distribution to tumor cells in HER2+ brain metastasis model systems [0.03%]
曲妥珠单抗deruxtecan的疗效，FcRn介导的血肿瘤屏障渗透以及在HER2阳性脑转移模型系统中的分布作用
Imran Khan,Dinesh Kumar,Wei Zhang et al.
Imran Khan et al.
Background: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) approved for metastatic HER2+ and HER2-low/ultralow breast cancer. It has shown impressive clinical activity for HER2+ brain metastases. We co...
Dana Silverbush,Liv Jürgensen,Nelson F Freeburg et al.
Dana Silverbush et al.
Background: Cellular heterogeneity is a defining feature of glioblastoma (GBM), shaping tumor progression and therapeutic response. While single-cell profiling resolves this heterogeneity, it remains impractical for large...
MBD3 deficiency decommissions the NuRD complex and orchestrates the epigenetic regulation of gene expression to suppress neuroblastoma progression [0.03%]
MBD3缺乏使NuRD复合体失效并协调基因表达的表观遗传调控以抑制神经母细胞瘤的发展
Chen Chen,Bize Guo,Siyan Wu et al.
Chen Chen et al.
Background: Neuroblastoma (NB) is the most common extracranial solid tumor in children and accounts for 15% of childhood cancer death. The nucleosome remodeling and deacetylase (NuRD) complex is a major chromatin remodeli...
Bo Deng,Rania Head,Kaspar Draaisma et al.
Bo Deng et al.
Background: Although the genetic evolution of IDHwt glioblastomas has extensively been investigated, limited studies have addressed the epigenetic evolution. Understanding the epigenetic evolution is particularly relevant...
Metabolic Profiling Defines Glioblastoma Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities [0.03%]
代谢谱分析定义了具有不同预后和治疗弱点的胶质母细胞瘤亚型
Fan Wu,Yi-Yun Yin,Di Wang et al.
Fan Wu et al.
Background: Glioblastoma (GBM) is a highly aggressive brain tumor with profound metabolic heterogeneity. However, a clinically actionable classification based on metabolic gene expression remains undefined. ...
Multimodality mapping of immunotherapy distribution as a predictive marker in glioma [0.03%]
免疫治疗分布的多模态映射作为胶质瘤的预测标记物
Jonas G Scheck,Berin Boztepe,Julius M Kernbach et al.
Jonas G Scheck et al.
Background: Scarce T cell infiltration, immunosuppressive tumor-associated macrophages and ineffective drug delivery drive glioma progression and limit treatment efficacy. Mapping immunotherapy distribution by multimodali...